These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 32027657)

  • 1. TLR5 agonist entolimod reduces the adverse toxicity of TNF while preserving its antitumor effects.
    Haderski GJ; Kandar BM; Brackett CM; Toshkov IM; Johnson CP; Paszkiewicz GM; Natarajan V; Gleiberman AS; Gudkov AV; Burdelya LG
    PLoS One; 2020; 15(2):e0227940. PubMed ID: 32027657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Toll-like receptor 5 agonist entolimod suppresses hepatic metastases in a murine model of ocular melanoma via an NK cell-dependent mechanism.
    Yang H; Brackett CM; Morales-Tirado VM; Li Z; Zhang Q; Wilson MW; Benjamin C; Harris W; Waller EK; Gudkov AV; Burdelya LG; Grossniklaus HE
    Oncotarget; 2016 Jan; 7(3):2936-50. PubMed ID: 26655090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Central role of liver in anticancer and radioprotective activities of Toll-like receptor 5 agonist.
    Burdelya LG; Brackett CM; Kojouharov B; Gitlin II; Leonova KI; Gleiberman AS; Aygun-Sunar S; Veith J; Johnson C; Haderski GJ; Stanhope-Baker P; Allamaneni S; Skitzki J; Zeng M; Martsen E; Medvedev A; Scheblyakov D; Artemicheva NM; Logunov DY; Gintsburg AL; Naroditsky BS; Makarov SS; Gudkov AV
    Proc Natl Acad Sci U S A; 2013 May; 110(20):E1857-66. PubMed ID: 23630282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toll-like receptor-5 agonist Entolimod broadens the therapeutic window of 5-fluorouracil by reducing its toxicity to normal tissues in mice.
    Kojouharov BM; Brackett CM; Veith JM; Johnson CP; Gitlin II; Toshkov IA; Gleiberman AS; Gudkov AV; Burdelya LG
    Oncotarget; 2014 Feb; 5(3):802-14. PubMed ID: 24583651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mobilan: a recombinant adenovirus carrying Toll-like receptor 5 self-activating cassette for cancer immunotherapy.
    Mett V; Komarova EA; Greene K; Bespalov I; Brackett C; Gillard B; Gleiberman AS; Toshkov IA; Aygün-Sunar S; Johnson C; Karasik E; Bapardekar-Nair M; Kurnasov OV; Osterman AL; Stanhope-Baker PS; Morrison C; Moser MT; Foster BA; Gudkov AV
    Oncogene; 2018 Jan; 37(4):439-449. PubMed ID: 28967901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toll-like receptor-5 agonist, entolimod, suppresses metastasis and induces immunity by stimulating an NK-dendritic-CD8+ T-cell axis.
    Brackett CM; Kojouharov B; Veith J; Greene KF; Burdelya LG; Gollnick SO; Abrams SI; Gudkov AV
    Proc Natl Acad Sci U S A; 2016 Feb; 113(7):E874-83. PubMed ID: 26831100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A deimmunized and pharmacologically optimized Toll-like receptor 5 agonist for therapeutic applications.
    Mett V; Kurnasov OV; Bespalov IA; Molodtsov I; Brackett CM; Burdelya LG; Purmal AA; Gleiberman AS; Toshkov IA; Burkhart CA; Kogan YN; Andrianova EL; Gudkov AV; Osterman AL
    Commun Biol; 2021 Apr; 4(1):466. PubMed ID: 33846531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Psychopharmacology: neuroimmune signaling in psychiatric disease-developing vaccines against abused drugs using toll-like receptor agonists.
    Yang F; Kosten TR
    Psychopharmacology (Berl); 2019 Oct; 236(10):2899-2907. PubMed ID: 30726515
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protective effects of sea buckthorn polysaccharide extracts against LPS/d-GalN-induced acute liver failure in mice via suppressing TLR4-NF-κB signaling.
    Liu H; Zhang W; Dong S; Song L; Zhao S; Wu C; Wang X; Liu F; Xie J; Wang J; Wang Y
    J Ethnopharmacol; 2015 Dec; 176():69-78. PubMed ID: 26494508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced susceptibility of nonobese diabetic mice to TNF-alpha and D-galactosamine-mediated hepatocellular apoptosis and lethality.
    Bahjat FR; Dharnidharka VR; Fukuzuka K; Morel L; Crawford JM; Clare-Salzler MJ; Moldawer LL
    J Immunol; 2000 Dec; 165(11):6559-67. PubMed ID: 11086099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic effect of the TLR5 agonist CBLB502 and its downstream effector IL-22 against liver injury.
    Melin N; Sánchez-Taltavull D; Fahrner R; Keogh A; Dosch M; Büchi I; Zimmer Y; Medová M; Beldi G; Aebersold DM; Candinas D; Stroka D
    Cell Death Dis; 2021 Apr; 12(4):366. PubMed ID: 33824326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ATP-depleting carbohydrates prevent tumor necrosis factor receptor 1-dependent apoptotic and necrotic liver injury in mice.
    Latta M; Künstle G; Lucas R; Hentze H; Wendel A
    J Pharmacol Exp Ther; 2007 Jun; 321(3):875-83. PubMed ID: 17369282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inactivation of Sirt1 in mouse livers protects against endotoxemic liver injury by acetylating and activating NF-κB.
    Cui X; Chen Q; Dong Z; Xu L; Lu T; Li D; Zhang J; Zhang M; Xia Q
    Cell Death Dis; 2016 Oct; 7(10):e2403. PubMed ID: 27711079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Etoposide prevents apoptosis in mouse liver with D-galactosamine/lipopolysaccharide-induced fulminant hepatic failure resulting in reduction of lethality.
    Nakama T; Hirono S; Moriuchi A; Hasuike S; Nagata K; Hori T; Ido A; Hayashi K; Tsubouchi H
    Hepatology; 2001 Jun; 33(6):1441-50. PubMed ID: 11391533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protective effect of baicalin against lipopolysaccharide/D-galactosamine-induced liver injury in mice by up-regulation of heme oxygenase-1.
    Wan JY; Gong X; Zhang L; Li HZ; Zhou YF; Zhou QX
    Eur J Pharmacol; 2008 Jun; 587(1-3):302-8. PubMed ID: 18420187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protective effect of SKLB010 against D-galactosamine/lipopolysaccharide-induced acute liver failure via nuclear factor-κB signaling pathway in macrophages.
    Xie C; Jingjing W; Li X; Zeng F; Ma L; Li C; Wei Z; Peng A; Chen L
    Int Immunopharmacol; 2014 Aug; 21(2):261-8. PubMed ID: 24861250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TLR5 binding and activation by KMRC011, a flagellin-derived radiation countermeasure.
    Song WS; Kim JH; Choi CM; Lee WJ; Yoon SI
    Biochem Biophys Res Commun; 2019 Jan; 508(2):570-575. PubMed ID: 30509486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Toll-Like Receptor 5 Agonist Entolimod Mitigates Lethal Acute Radiation Syndrome in Non-Human Primates.
    Krivokrysenko VI; Toshkov IA; Gleiberman AS; Krasnov P; Shyshynova I; Bespalov I; Maitra RK; Narizhneva NV; Singh VK; Whitnall MH; Purmal AA; Shakhov AN; Gudkov AV; Feinstein E
    PLoS One; 2015; 10(9):e0135388. PubMed ID: 26367124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mitigation of Radiation-Induced Epithelial Damage by the TLR5 Agonist Entolimod in a Mouse Model of Fractionated Head and Neck Irradiation.
    Toshkov IA; Gleiberman AS; Mett VL; Hutson AD; Singh AK; Gudkov AV; Burdelya LG
    Radiat Res; 2017 May; 187(5):570-580. PubMed ID: 28323577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toll-like receptor 5 signaling restrains T-cell/natural killer T-cell activation and protects against concanavalin A-induced hepatic injury.
    Wang L; Zhang W; Ge CH; Yin RH; Xiao Y; Zhan YQ; Yu M; Li CY; Ge ZQ; Yang XM
    Hepatology; 2017 Jun; 65(6):2059-2073. PubMed ID: 28273362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.